Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25100412 | 0.75 | FOLH1 (0.39) | FOLH1DGAT1NPY1RTLR2 | |
| SCHEMBL22238237 | 0.74 | FOLH1 (0.41) | FOLH1DGAT1NPY1R | |
| SCHEMBL22300339 | 0.73 | GBA1 (0.36) | FOLH1DGAT1 | |
| SCHEMBL29351004 | 0.72 | TTR (0.46) | FOLH1DGAT1NPY1R | |
| SCHEMBL17740215 | 0.69 | OPRM1 (0.40) | FOLH1DGAT1 | |
| SCHEMBL17740005 | 0.69 | DRD2 (0.41) | FOLH1 | |
| SCHEMBL13936568 | 0.68 | GLP1R (0.52) | TLR2GLP1R | |
| SCHEMBL25724125 | 0.68 | DGAT1 (0.38) | FOLH1DGAT1 | |
| SCHEMBL21778353 | 0.67 | GLP1R (0.47) | TLR2GLP1R | |
| SCHEMBL25835931 | 0.67 | GBA1 (0.41) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DARS1, CD2, FCGR2A | FOLH1 282/4885DGAT1 2033/4885NPY1R 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.